180 Life Sciences prices 4.6M shares at 65c in public offering

180 Life Sciences announced the pricing of a public offering of 4,615,385 shares of the Company’s common stock and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share of $0.65. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are expected to be approximately $3 million, before deducting the placement agent’s fees and other offering expenses. The closing of the offering is expected to occur on or about August 14, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for research and development expenses and general corporate purposes, including the preparation of a marketing authorization application for Dupuytren’s Contracture in the U.K., and potentially the U.S., and legal expenses. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.